• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

解析继发性免疫缺陷:B 细胞淋巴增殖性疾病中的原发性免疫缺陷的鉴定。

Dissecting Secondary Immunodeficiency: Identification of Primary Immunodeficiency within B-Cell Lymphoproliferative Disorders.

机构信息

Department of Clinical Immunology, Institute of Laboratory Medicine and IdISSC, Hospital Clínico San Carlos, Madrid, Spain.

Department of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University, Madrid, Spain.

出版信息

J Clin Immunol. 2024 Oct 23;45(1):32. doi: 10.1007/s10875-024-01818-2.

DOI:10.1007/s10875-024-01818-2
PMID:39441407
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11499357/
Abstract

Distinguishing between primary (PID) and secondary (SID) immunodeficiencies, particularly in relation to hematological B-cell lymphoproliferative disorders (B-CLPD), poses a major clinical challenge. We aimed to analyze and define the clinical and laboratory variables in SID patients associated with B-CLPD, identifying overlaps with late-onset PIDs, which could potentially improve diagnostic precision and prognostic assessment. We studied 37 clinical/laboratory variables in 151 SID patients with B-CLPD. Patients were classified as "Suspected PID Group" when having recurrent-severe infections prior to the B-CLPD and/or hypogammaglobulinemia according to key ESID criteria for PID. Bivariate association analyses showed significant statistical differences between "Suspected PID"- and "SID"-groups in 10 out of 37 variables analyzed, with "Suspected PID" showing higher frequencies of childhood recurrent-severe infections, family history of B-CLPD, significantly lower serum Free Light Chain (sFLC), immunoglobulin concentrations, lower total leukocyte, and switch-memory B-cell counts at baseline. Rpart machine learning algorithm was performed to potentially create a model to differentiate both groups. The model developed a decision tree with two major variables in order of relevance: sum κ + λ and history of severe-recurrent infections in childhood, with high sensitivity 89.5%, specificity 100%, and accuracy 91.8% for PID prediction. Identifying significant clinical and immunological variables can aid in the difficult task of recognizing late-onset PIDs among SID patients, emphasizing the value of a comprehensive immunological evaluation. The differences between "Suspected PID" and SID groups, highlight the need of early, tailored diagnostic and treatment strategies for personalized patient management and follow up.

摘要

区分原发性(PID)和继发性(SID)免疫缺陷,特别是与血液学 B 细胞淋巴增殖性疾病(B-CLPD)相关,是一项重大的临床挑战。我们旨在分析和定义 SID 患者与 B-CLPD 相关的临床和实验室变量,确定与迟发性 PID 的重叠,这可能有助于提高诊断精度和预后评估。我们研究了 151 例 SID 患者伴 B-CLPD 的 37 项临床/实验室变量。当患者在 B-CLPD 之前有复发性严重感染和/或根据 PID 的关键 ESID 标准存在低丙种球蛋白血症时,将其归类为“疑似 PID 组”。二变量关联分析显示,在分析的 37 个变量中有 10 个在“疑似 PID”和“SID”组之间存在显著的统计学差异,“疑似 PID”组的儿童复发性严重感染、B-CLPD 家族史、显著较低的血清游离轻链(sFLC)、免疫球蛋白浓度、较低的总白细胞和初始记忆 B 细胞计数的频率更高。Rpart 机器学习算法用于潜在地创建一个模型来区分这两组。该模型开发了一个决策树,其中两个主要变量按相关性排序:总和 κ + λ 和儿童期严重复发性感染史,对 PID 的预测具有高敏感性 89.5%、特异性 100%和准确性 91.8%。确定重要的临床和免疫学变量可以帮助识别 SID 患者中的迟发性 PID,强调全面免疫评估的价值。“疑似 PID”和 SID 组之间的差异突出了为个体化患者管理和随访制定早期、定制的诊断和治疗策略的必要性。

相似文献

1
Dissecting Secondary Immunodeficiency: Identification of Primary Immunodeficiency within B-Cell Lymphoproliferative Disorders.解析继发性免疫缺陷:B 细胞淋巴增殖性疾病中的原发性免疫缺陷的鉴定。
J Clin Immunol. 2024 Oct 23;45(1):32. doi: 10.1007/s10875-024-01818-2.
2
Secondary Immune Deficiency and Primary Immune Deficiency Crossovers: Hematological Malignancies and Autoimmune Diseases.继发性免疫缺陷和原发性免疫缺陷的交叉:血液系统恶性肿瘤和自身免疫性疾病。
Front Immunol. 2022 Jul 18;13:928062. doi: 10.3389/fimmu.2022.928062. eCollection 2022.
3
EuroFlow-Based Flowcytometric Diagnostic Screening and Classification of Primary Immunodeficiencies of the Lymphoid System.基于 EuroFlow 的流式细胞术诊断性筛查和淋巴系统原发性免疫缺陷的分类。
Front Immunol. 2019 Jun 13;10:1271. doi: 10.3389/fimmu.2019.01271. eCollection 2019.
4
Serum Free Light Chains in Common Variable Immunodeficiency Disorders: Role in Differential Diagnosis and Association With Clinical Phenotype.常见可变免疫缺陷病中的血清游离轻链:在鉴别诊断中的作用及与临床表型的关联。
Front Immunol. 2020 Mar 31;11:319. doi: 10.3389/fimmu.2020.00319. eCollection 2020.
5
Evaluation of the Effectiveness of the 6 Warning Signs of the European Society for Immunodeficiencies for Primary Immunodeficiencies in Older Adults.评估欧洲免疫缺陷学会 6 大预警信号在老年原发性免疫缺陷中的有效性。
Int Arch Allergy Immunol. 2024;185(4):402-410. doi: 10.1159/000535604. Epub 2024 Jan 12.
6
Specific Cellular and Humoral Immune Responses to the Neoantigen RBD of SARS-CoV-2 in Patients with Primary and Secondary Immunodeficiency and Healthy Donors.原发性和继发性免疫缺陷患者及健康供体对新冠病毒新抗原RBD的特异性细胞免疫和体液免疫反应
Biomedicines. 2023 Mar 28;11(4):1042. doi: 10.3390/biomedicines11041042.
7
[Primary immunodeficiencies. Clinical features and variant forms].[原发性免疫缺陷病。临床特征及变异形式]
Allergol Immunopathol (Madr). 2001 May-Jun;29(3):101-7. doi: 10.1016/s0301-0546(01)79027-1.
8
Primary Immunodeficiency Disorders Among North Indian Children.原发性免疫缺陷病在印度北部儿童中的发病情况。
Indian J Pediatr. 2019 Oct;86(10):885-891. doi: 10.1007/s12098-019-02971-y. Epub 2019 Jun 8.
9
The Euroflow PID Orientation Tube in the diagnostic workup of primary immunodeficiency: Daily practice performance in a tertiary university hospital.Euroflow PID 定向管在原发性免疫缺陷诊断中的应用:三级大学医院的日常实践表现。
Front Immunol. 2022 Sep 13;13:937738. doi: 10.3389/fimmu.2022.937738. eCollection 2022.
10
Primary and Secondary Immunodeficiency Diseases in Oncohaematology: Warning Signs, Diagnosis, and Management.原发性和继发性免疫缺陷病在肿瘤血液学中的表现:警示征象、诊断和处理。
Front Immunol. 2019 Mar 26;10:586. doi: 10.3389/fimmu.2019.00586. eCollection 2019.

本文引用的文献

1
An Exploratory Approach of Clinically Useful Biomarkers of Cvid by Logistic Regression.采用逻辑回归方法对 CVID 的临床有用生物标志物进行探索性研究。
J Clin Immunol. 2024 Jun 7;44(6):143. doi: 10.1007/s10875-024-01746-1.
2
Immune dysregulation as a leading principle for lymphoma development in diverse immunological backgrounds.免疫失调作为不同免疫背景下淋巴瘤发生的主要原则。
Immunol Lett. 2023 Nov;263:46-59. doi: 10.1016/j.imlet.2023.08.007. Epub 2023 Sep 27.
3
The Rapidly Expanding Genetic Spectrum of Common Variable Immunodeficiency-Like Disorders.
常见可变免疫缺陷样疾病的遗传谱迅速扩大。
J Allergy Clin Immunol Pract. 2023 Jun;11(6):1646-1664. doi: 10.1016/j.jaip.2023.01.048. Epub 2023 Feb 14.
4
Genomic crossroads between non-Hodgkin's lymphoma and common variable immunodeficiency.非霍奇金淋巴瘤与普通变异性免疫缺陷之间的基因组交叉路口。
Front Immunol. 2022 Aug 5;13:937872. doi: 10.3389/fimmu.2022.937872. eCollection 2022.
5
Secondary Immune Deficiency and Primary Immune Deficiency Crossovers: Hematological Malignancies and Autoimmune Diseases.继发性免疫缺陷和原发性免疫缺陷的交叉:血液系统恶性肿瘤和自身免疫性疾病。
Front Immunol. 2022 Jul 18;13:928062. doi: 10.3389/fimmu.2022.928062. eCollection 2022.
6
Secondary rituximab-associated versus primary immunodeficiencies: The enigmatic border.继发性利妥昔单抗相关免疫缺陷与原发性免疫缺陷:神秘的边界。
Eur J Immunol. 2022 Oct;52(10):1572-1580. doi: 10.1002/eji.202149667. Epub 2022 Aug 10.
7
Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee.人类先天性免疫缺陷:国际免疫学联盟专家委员会 2022 年更新的分类。
J Clin Immunol. 2022 Oct;42(7):1473-1507. doi: 10.1007/s10875-022-01289-3. Epub 2022 Jun 24.
8
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.《世界卫生组织造血与淋巴组织肿瘤分类》第五版:淋巴肿瘤。
Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22.
9
Genomic characterization of lymphomas in patients with inborn errors of immunity.免疫缺陷相关淋巴瘤的基因组特征
Blood Adv. 2022 Sep 27;6(18):5403-5414. doi: 10.1182/bloodadvances.2021006654.
10
Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees.继发性低丙种球蛋白血症的诊断和管理实用指南:美国过敏、哮喘和免疫学学会原发性免疫缺陷和免疫反应改变工作组的报告。
J Allergy Clin Immunol. 2022 May;149(5):1525-1560. doi: 10.1016/j.jaci.2022.01.025. Epub 2022 Feb 14.